CytomX Therapeutics (CTMX) PT Lowered to $3.56 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Etzer Darout lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $3.56 (from $3.59) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
